*The following content is generated by AI and is for reference only.
Carteolol is a non-selective beta-adrenergic blocking agent widely utilized in the management of cardiovascular disorders, particularly hypertension and angina pectoris. Chemically known as 1-(tert-butylamino)-3-[[(4-methylphenyl)sulfonyl]oxy]-2-propanol, it possesses the molecular formula C15H25NO4S and carries the CAS Registry Number 6907-83-9. This compound belongs to the class of arylalkanolamines and functions by competitively inhibiting both beta-1 and beta-2 adrenergic receptors. Unlike some other beta-blockers, Carteolol exhibits partial agonist activity, often referred to as intrinsic sympathomimetic activity (ISA), which may result in less bradycardia at rest compared to agents lacking this property.
In clinical practice, Carteolol is primarily administered orally for the long-term control of high blood pressure. By reducing heart rate and myocardial contractility, it decreases cardiac output and subsequently lowers systemic arterial pressure. It is also effective in preventing episodes of chest pain associated with coronary artery disease by balancing oxygen supply and demand within the heart muscle. Furthermore, its ophthalmic formulation is frequently prescribed to treat elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, offering a convenient topical delivery method that minimizes systemic side effects.
The pharmacokinetic profile of Carteolol includes rapid absorption after oral administration, with significant hepatic metabolism via cytochrome P450 enzymes before excretion. Patients with asthma, severe bradycardia, or cardiogenic shock are generally contraindicated from using this medication due to its non-selective nature. While it offers therapeutic benefits for various hemodynamic conditions, careful monitoring is required during initiation and dose adjustments. Overall, Carteolol remains a valuable tool in modern cardiology and ophthalmology, providing effective symptom relief and disease management through its unique dual-action mechanism on adrenergic signaling pathways. Its availability in multiple formulations ensures flexibility in treating diverse patient needs across different medical specialties globally.